KR20050088291A - 아데노신 a3 수용체 리간드로서의 이미다조퀴놀린 유도체 - Google Patents
아데노신 a3 수용체 리간드로서의 이미다조퀴놀린 유도체 Download PDFInfo
- Publication number
- KR20050088291A KR20050088291A KR1020057008683A KR20057008683A KR20050088291A KR 20050088291 A KR20050088291 A KR 20050088291A KR 1020057008683 A KR1020057008683 A KR 1020057008683A KR 20057008683 A KR20057008683 A KR 20057008683A KR 20050088291 A KR20050088291 A KR 20050088291A
- Authority
- KR
- South Korea
- Prior art keywords
- group
- formula
- branched
- straight
- salts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HUP0203976 | 2002-11-15 | ||
HU0203976A HUP0203976A3 (en) | 2002-11-15 | 2002-11-15 | Adenozine a3 receptors, process for their preparation and pharmaceutical compositions containing them |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20050088291A true KR20050088291A (ko) | 2005-09-05 |
Family
ID=90001561
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020057008683A Abandoned KR20050088291A (ko) | 2002-11-15 | 2003-11-11 | 아데노신 a3 수용체 리간드로서의 이미다조퀴놀린 유도체 |
Country Status (35)
Country | Link |
---|---|
US (2) | US7419977B2 (is) |
EP (1) | EP1560828B9 (is) |
JP (1) | JP4533148B2 (is) |
KR (1) | KR20050088291A (is) |
CN (1) | CN1332960C (is) |
AR (1) | AR041968A1 (is) |
AT (1) | ATE325123T1 (is) |
AU (1) | AU2003282263B2 (is) |
BR (1) | BR0316355A (is) |
CA (1) | CA2505910C (is) |
CO (1) | CO5690577A2 (is) |
CY (1) | CY1105180T1 (is) |
DE (1) | DE60305058T2 (is) |
DK (1) | DK1560828T3 (is) |
EA (1) | EA007595B1 (is) |
ES (1) | ES2263039T3 (is) |
HK (1) | HK1077819A1 (is) |
HR (1) | HRP20050540A2 (is) |
HU (1) | HUP0203976A3 (is) |
IL (1) | IL168516A (is) |
IS (1) | IS2456B (is) |
MA (1) | MA27501A1 (is) |
ME (1) | MEP19008A (is) |
MX (1) | MXPA05005198A (is) |
NO (1) | NO20052866D0 (is) |
NZ (1) | NZ540029A (is) |
PL (1) | PL376837A1 (is) |
PT (1) | PT1560828E (is) |
RS (1) | RS51320B (is) |
SI (1) | SI1560828T1 (is) |
TN (1) | TNSN05133A1 (is) |
TW (1) | TWI248934B (is) |
UA (1) | UA78889C2 (is) |
WO (1) | WO2004046146A1 (is) |
ZA (1) | ZA200503807B (is) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUP0105406A3 (en) * | 2001-12-21 | 2003-12-29 | Sanofi Aventis | Imidazo[1,2-a]quinolin derivatives, process for their preparation, pharmaceutical compositions thereof and intermediates |
HUP0203976A3 (en) * | 2002-11-15 | 2004-08-30 | Sanofi Aventis | Adenozine a3 receptors, process for their preparation and pharmaceutical compositions containing them |
HUP0400812A2 (en) * | 2004-04-19 | 2006-02-28 | Sanofi Aventis | Crystalline forms of 2-amino-3-cyano-quinoline derivatives, process for their preparation and pharmaceutical compositions containing them |
GT200600381A (es) | 2005-08-25 | 2007-03-28 | Compuestos organicos | |
US20090088403A1 (en) * | 2007-05-07 | 2009-04-02 | Randy Blakely | A3 adenosine receptors as targets for the modulation of central serotonergic signaling |
HUP0700395A2 (en) * | 2007-06-07 | 2009-03-02 | Sanofi Aventis | Substituted [1,2,4] triazolo [1,5-a] quinolines, process for their preparation, pharmaceutical compositions thereof, and intermediates |
EP2456419B1 (en) | 2009-07-21 | 2016-11-23 | Oradin Pharmaceutical Ltd. | A3 adenosine receptor ligands for modulation of pigmentation |
CA2898018C (en) | 2013-02-01 | 2021-02-09 | Wellstat Therapeutics Corporation | Substituted quinolin-4-amine compounds and pharmaceutical compositions thereof having anti-inflammatory, antifungal, antiparasitic and anticancer activity |
KR101820909B1 (ko) * | 2017-07-07 | 2018-01-23 | 퓨쳐메디신 주식회사 | 아데노신 유도체를 포함하는 만성신장질환 예방 및 치료용 약학적 조성물 |
AU2018334272B2 (en) | 2017-09-15 | 2023-06-15 | Forma Therapeutics, Inc. | Tetrahydro-imidazo quinoline compositions as CBP/p300 inhibitors |
AU2019295790B2 (en) | 2018-06-29 | 2023-07-13 | Forma Therapeutics, Inc. | Inhibiting creb binding protein (CBP) |
MX2021010829A (es) * | 2019-03-15 | 2021-12-10 | Forma Therapeutics Inc | Inhibición de la proteína de unión al elemento de respuesta a adenosín monofosfato (amp) cíclica (creb). |
US11801243B2 (en) | 2020-09-23 | 2023-10-31 | Forma Therapeutics, Inc. | Bromodomain inhibitors for androgen receptor-driven cancers |
US11795168B2 (en) | 2020-09-23 | 2023-10-24 | Forma Therapeutics, Inc. | Inhibiting cyclic amp-responsive element-binding protein (CREB) binding protein (CBP) |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4075343A (en) * | 1976-09-13 | 1978-02-21 | Pfizer Inc. | Anti-allergenic 5-alkoxyimidazo[1,2-A]quinoline-2-carboxylic acids and derivatives thereof |
GB1596652A (en) * | 1977-01-20 | 1981-08-26 | Roussel Lab Ltd | Imidazo (1,2-a) quinoline-2-carboxylic acid and derivatives |
US4644002A (en) | 1979-02-09 | 1987-02-17 | Roussel Uclaf | Imidazo[2,1-C]quinolines, useful as antiallergic agents |
IL59104A (en) * | 1979-02-09 | 1984-02-29 | Roussel Uclaf | Heterotricyclic derivatives,process for their preparation and pharmaceutical compositions incorporating them |
FR2448541A1 (fr) | 1979-02-09 | 1980-09-05 | Roussel Uclaf | Nouveaux derives de l'oxoimidazoquinoxaline et leurs sels, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant |
WO2000002861A1 (en) | 1998-07-10 | 2000-01-20 | The United States Of America, Represented By Secretary, Department Of Health And Human Services | A3 adenosine receptor antagonists |
US6448253B1 (en) * | 1998-09-16 | 2002-09-10 | King Pharmaceuticals Research And Development, Inc. | Adenosine A3 receptor modulators |
CN1207298C (zh) | 1999-09-28 | 2005-06-22 | 株式会社大塚制药工厂 | 三唑并嘌呤衍生物、含有该衍生物的药物组合物和腺苷a3受体亲和剂 |
US7160890B2 (en) * | 1999-12-02 | 2007-01-09 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A3 receptor and uses thereof |
YU42703A (sh) * | 2000-12-01 | 2006-03-03 | Osi Pharmaceuticals Inc. | Jedinjenja specifična za dobijanje adenozinske a1,a2a i a3 receptore i njihove primene |
RU2278112C2 (ru) | 2001-05-31 | 2006-06-20 | Санофи-Авентис | Производные аминохинолина и аминопиридина и их применение в качестве лигандов аденозина a3 |
HUP0105406A3 (en) | 2001-12-21 | 2003-12-29 | Sanofi Aventis | Imidazo[1,2-a]quinolin derivatives, process for their preparation, pharmaceutical compositions thereof and intermediates |
HUP0105407A3 (en) * | 2001-12-21 | 2004-04-28 | Sanofi Aventis | Triazolo[1,5-a]quinolin derivatives, process for their preparation, pharmaceutical compositions thereof and intermediates |
HUP0203976A3 (en) | 2002-11-15 | 2004-08-30 | Sanofi Aventis | Adenozine a3 receptors, process for their preparation and pharmaceutical compositions containing them |
-
2002
- 2002-11-15 HU HU0203976A patent/HUP0203976A3/hu unknown
-
2003
- 2003-11-11 CN CNB2003801062293A patent/CN1332960C/zh not_active Expired - Fee Related
- 2003-11-11 DK DK03773882T patent/DK1560828T3/da active
- 2003-11-11 AU AU2003282263A patent/AU2003282263B2/en not_active Ceased
- 2003-11-11 UA UAA200505875A patent/UA78889C2/uk unknown
- 2003-11-11 KR KR1020057008683A patent/KR20050088291A/ko not_active Abandoned
- 2003-11-11 ME MEP-190/08A patent/MEP19008A/xx unknown
- 2003-11-11 AT AT03773882T patent/ATE325123T1/de active
- 2003-11-11 ES ES03773882T patent/ES2263039T3/es not_active Expired - Lifetime
- 2003-11-11 CA CA2505910A patent/CA2505910C/en not_active Expired - Fee Related
- 2003-11-11 SI SI200330299T patent/SI1560828T1/sl unknown
- 2003-11-11 PT PT03773882T patent/PT1560828E/pt unknown
- 2003-11-11 DE DE60305058T patent/DE60305058T2/de not_active Expired - Lifetime
- 2003-11-11 BR BR0316355-5A patent/BR0316355A/pt not_active IP Right Cessation
- 2003-11-11 MX MXPA05005198A patent/MXPA05005198A/es active IP Right Grant
- 2003-11-11 WO PCT/HU2003/000095 patent/WO2004046146A1/en active IP Right Grant
- 2003-11-11 RS YUP-2005/0364A patent/RS51320B/sr unknown
- 2003-11-11 NZ NZ540029A patent/NZ540029A/en not_active IP Right Cessation
- 2003-11-11 PL PL376837A patent/PL376837A1/pl not_active Application Discontinuation
- 2003-11-11 EP EP03773882A patent/EP1560828B9/en not_active Expired - Lifetime
- 2003-11-11 EA EA200500830A patent/EA007595B1/ru unknown
- 2003-11-11 JP JP2004552920A patent/JP4533148B2/ja not_active Expired - Fee Related
- 2003-11-14 AR ARP030104200A patent/AR041968A1/es unknown
- 2003-11-14 TW TW092131901A patent/TWI248934B/zh not_active IP Right Cessation
-
2005
- 2005-05-10 IL IL168516A patent/IL168516A/en not_active IP Right Cessation
- 2005-05-10 TN TNP2005000133A patent/TNSN05133A1/en unknown
- 2005-05-11 ZA ZA200503807A patent/ZA200503807B/en unknown
- 2005-05-16 US US11/130,429 patent/US7419977B2/en not_active Expired - Fee Related
- 2005-05-31 IS IS7874A patent/IS2456B/is unknown
- 2005-06-13 MA MA28334A patent/MA27501A1/fr unknown
- 2005-06-13 NO NO20052866A patent/NO20052866D0/no not_active Application Discontinuation
- 2005-06-14 CO CO05057645A patent/CO5690577A2/es not_active Application Discontinuation
- 2005-06-14 HR HR20050540A patent/HRP20050540A2/xx not_active Application Discontinuation
- 2005-11-07 HK HK05109885A patent/HK1077819A1/xx not_active IP Right Cessation
-
2006
- 2006-07-28 CY CY20061101054T patent/CY1105180T1/el unknown
-
2008
- 2008-06-17 US US12/140,512 patent/US7709489B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7709489B2 (en) | Imidazoquinoline derivatives as adenosine A3 receptor ligands | |
JP2011042653A (ja) | アデノシン受容体リガンドとして有用なトリアゾロ−キノリン誘導体 | |
EP2173346A2 (en) | Use of compounds for preparing anti-tuberculosis agents | |
EP2167470B1 (en) | Triazolo [1, 5-a]quinolines as adenosine a3 receptor ligands | |
KR100745307B1 (ko) | 아미노퀴놀린 유도체 및 아데노신 a3 리간드로서의 이의 용도 | |
KR20060065662A (ko) | 아미노퀴놀린 유도체 및 아데노신 a3 리간드로서의 이의용도 | |
JP4530663B2 (ja) | イミダゾキノリン誘導体 | |
KR20070020335A (ko) | 아미노퀴놀린 유도체 및 아데노신 a3 리간드로서의 이의용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PA0105 | International application |
Patent event date: 20050513 Patent event code: PA01051R01D Comment text: International Patent Application |
|
PG1501 | Laying open of application | ||
A201 | Request for examination | ||
PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20081110 Comment text: Request for Examination of Application |
|
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20101223 Patent event code: PE09021S01D |
|
E701 | Decision to grant or registration of patent right | ||
PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20111017 |
|
NORF | Unpaid initial registration fee | ||
PC1904 | Unpaid initial registration fee |